Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 20;13(4):886.
doi: 10.3390/cancers13040886.

Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)

Bernd Kasper  1 , Annie Achee  2 , Kathrin Schuster  3 , Roger Wilson  3 , Gerard van Oortmerssen  3 , Rebecca A Gladdy  4 , Matthew L Hemming  5 , Paul Huang  6 , Matthew Ingham  7 , Robin L Jones  6   8 , Seth M Pollack  9 , Denise Reinke  10 , Roberta Sanfilippo  11 , Scott M Schuetze  12 , Neeta Somaiah  13 , Brian A Van Tine  14 , Breelyn Wilky  15 , Scott Okuno  16 , Jonathan Trent  17
Affiliations
Review

Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)

Bernd Kasper et al. Cancers (Basel). .

Abstract

As leiomyosarcoma patients are challenged by the development of metastatic disease, effective systemic therapies are the cornerstone of outcome. However, the overall activity of the currently available conventional systemic treatments and the prognosis of patients with advanced or metastatic disease are still poor, making the treatment of this patient group challenging. Therefore, in a joint effort together with patient networks and organizations, namely Sarcoma Patients EuroNet (SPAEN), the international network of sarcoma patients organizations, and the National LeioMyoSarcoma Foundation (NLMSF) in the United States, we aim to summarize state-of-the-art treatments for leiomyosarcoma patients in order to identify knowledge gaps and current unmet needs, thereby guiding the community to design innovative clinical trials and basic research and close these research gaps. This position paper arose from a leiomyosarcoma research meeting in October 2020 hosted by the NLMSF and SPAEN.

Keywords: NLMSF; SPAEN; leiomyosarcoma; research; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
New possible treatment strategies and their mode of action for patients with LMS.
Figure 2
Figure 2
Future perspectives for the management of patients diagnosed with LMS.
See this image and copyright information in PMC

References

    1. Martin-Liberal J. Leiomyosarcoma: Principles of management. Intractable Rare Dis. Res. 2013;2:127–129. doi: 10.5582/irdr.2013.v2.4.127. - DOI - PMC - PubMed
    1. Reichardt P. Soft tissue sarcomas, a look into the future: Different treatments for different subtypes. Future Oncol. 2014;10(Suppl. 8):s19–s27. doi: 10.2217/fon.14.116. - DOI - PubMed
    1. Ikoma N., Torres K.E., Lin H.Y., Ravi V., Roland C.L., Mann G.N., Hunt K.K., Cormier J.N., Feig B.W. Recurrence patterns of retroperitoneal leiomyosarcoma and impact of salvage surgery. J. Surg. Oncol. 2017;116:313–319. doi: 10.1002/jso.24667. - DOI - PMC - PubMed
    1. Martin-Liberal J., Benson C. Systemic chemotherapy for inoperable, locally advanced, recurrent or metastatic uterine leiomyosarcoma. Clin. Oncol. (R. Coll. Radiol.) 2013;25:343–345. doi: 10.1016/j.clon.2013.02.006. - DOI - PubMed
    1. Italiano A., Toulmonde M., Stoeckle E., Kind M., Kantor G., Coindre J.-M., Bui B. Clinical outcome of leiomyosarcomas of vascular origin: Comparison with leiomyosarcomas of other origin. Ann. Oncol. 2010;21:1915–1921. doi: 10.1093/annonc/mdq039. - DOI - PubMed

LinkOut - more resources